Standard BioTools Inc.
LABNASDAQHealthcare● Active
$0.80
$-0.35(-30.16%)
Market Cap$313543667
P/E Ratio—
52W High$1.72
52W Low$0.7953
Standard BioTools Inc. (LAB) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · LAB · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($74.90M) | ($138.88M) | ($74.66M) | ($190.10M) | ($59.24M) |
| Depreciation & Amort. | $1.72M | $16.86M | $15.18M | $15.03M | $16.20M |
| Stock-Based Comp. | $29.61M | $31.73M | $13.12M | $14.88M | $16.10M |
| Change in Working Capital | ($44.98M) | ($12.08M) | $1.79M | ($12.35M) | ($18.01M) |
| Net Cash from Operations | ($74.35M) | ($143.45M) | ($43.29M) | ($89.37M) | ($44.06M) |
| Investing Activities | |||||
| Capital Expenditure | ($8.30M) | ($8.36M) | ($2.83M) | ($3.83M) | ($13.26M) |
| Purchases of Investments | ($140.93M) | $0.00M | ($94.90M) | $0.00M | $0.00M |
| Sales of Investments | $179.00M | $0.00M | $117.96M | $0.00M | $0.00M |
| Net Cash from Investing | $24.77M | $363.17M | $20.24M | ($88.13M) | ($11.95M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | ($40.95M) | ($5.41M) | ($0.77M) | ($1.79M) |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | ($63.19M) | ($2.08M) | $18.16M | $9.50M |
| Net Cash from Financing | $0.57M | ($102.62M) | ($6.81M) | $230.76M | $15.96M |
| Free Cash Flow | |||||
| Free Cash Flow | ($82.65M) | ($151.81M) | ($46.12M) | ($93.19M) | ($57.33M) |
| FCF Margin %(computed) | -96.86% | -87.03% | -43.37% | -95.15% | -43.90% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Standard BioTools Inc. data
About Standard BioTools Inc. (LAB) Cash Flow Statement
Standard BioTools Inc. generated operating cash flow of ($0.07B) and free cash flow of ($0.08B) for 2025 — a FCF margin of -96.86%. Capital expenditure was ($0.01B).
Frequently asked questions
LAB · 4 questionsStandard BioTools Inc. generated free cash flow of ($0.08B) for 2025, up 45.6% year-over-year.
LAB free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10